20201216 PR Investors Meeting agenda Jan 2021
Category: Press release
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
20201203 – TG4001 mini oral prez ESMO IO EN
Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
20201203 – Nomination Transgene – EN
Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201109 Transgene BioInvent_SITC BT001_EN
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
20201109 – TG4001+avelumab presentation poster SITC – EN
Transgene reports business update and end Q3 2020 financial position
20201105 Transgene Q3 business upradta EN
Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
20201105 TG – Neoantigen summit presentation
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201027 – TG4001+avelumab abstract data SITC – EN
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201019 TG4001+avelumab SITC – EN
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201015 – BT-001_SITC poster EN